Tesamorelin

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH), with a trans-3-hexenoic acid modification that protects it from enzymatic degradation. It is marketed as Egrifta and is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is one of the few GHRH analogs with a formal FDA approval and is well-studied for visceral adipose tissue reduction. Research-grade tesamorelin is sold for laboratory use.

Tesamorelin is a long-acting cousin of natural GHRH. It tells the pituitary to release growth hormone in natural pulses — the same way your body normally does — and is uniquely studied for its ability to reduce visceral fat (the deep belly fat surrounding organs). It is the only GHRH analog that has full FDA approval, originally for HIV-associated belly fat accumulation, and has become popular off-label for visceral fat reduction in metabolic research.

Tesamorelin binds the GHRH receptor on pituitary somatotrophs, triggering pulsatile growth hormone release. The downstream effects include increased IGF-1, increased lipolysis (especially of visceral fat), and modest improvements in body composition. The modification at the N-terminus extends its half-life enough for once-daily dosing while preserving the natural pulse pattern.

• •HIV-associated lipodystrophy (FDA-approved indication)
• •Visceral adipose tissue reduction
• •Cognitive function in HIV patients
• •Non-alcoholic fatty liver disease research
• •Cardiometabolic outcomes

Tesamorelin is the GHRH analog of choice for users specifically targeting visceral fat. Compared with CJC-1295, it has more focused belly-fat data and FDA approval, but it is more expensive. Many users cycle tesamorelin with a GHRP like ipamorelin for amplified GH pulses.

“The belly-fat GHRH with the FDA stamp.”

Almost always discussed with ipamorelin or another GHRP for GH-pulse amplification — the classic 'GHRH + GHRP' pairing. Sometimes combined with BPC-157 for recovery during cuts.

Tesamorelin is an FDA-approved GHRH analog used for HIV-associated lipodystrophy and widely studied off-label for visceral fat reduction. It produces pulsatile GH release and is sold as Egrifta and as research-grade peptide.